EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Characteristics and Management of Immune Checkpoint Inhibitor-Associated Sicca Syndrome

Meridith L Balbach iD, Douglas B Johnson

Cancers · 04.06.2026 · 18 (11) · 1836

DOI: 10.3390/cancers18111836 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 04.06.2026. Verfasst von Meridith L Balbach und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology and Immunology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, Department of Defense, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) can induce a sicca-like syndrome that differs from primary Sjögren’s disease in both immunopathogenesis and clinical phenotype. Despite growing recognition of this entity, data describing real-world management and outcomes, particularly in the context of ICI discontinuation and rechallenge, remain limited.

Methods

Patients with new onset of sicca syndrome or exacerbation of previous symptoms following ICI therapy were retrospectively identified and assessed.

Results

Fifty-nine patients with diverse malignancies (including melanoma, gastrointestinal, genitourinary, etc.) and sicca syndrome following treatment with ICIs (most often pembrolizumab or nivolumab +/− ipilimumab) were evaluated. Acute-onset dry mouth, primarily CTCAE v6.0 grades 1 (n = 24, 40.7%) and 2 (n = 34, 57.6%), occurred at a median of 104 days after ICI initiation, sometimes with associated dry eye (n = 8, 13.6%). Most were managed conservatively with behavioral modification and over-the-counter therapies alone (n = 37, 62.7%) while others received sialagogues (n = 9, 15.3%), dexamethasone oral rinse (n = 11, 18.6%), and/or systemic corticosteroids (n = 16, 27.1%). Additional management strategies included de-escalation to ICI monotherapy (n = 5, 8.5%) or discontinued ICI (n = 6, 10.2%). Half of patients treated with corticosteroids demonstrated subjective improvement in symptoms while 75% improved following ICI discontinuation. Four patients underwent rechallenge after a median interruption of 564 days; all (n = 4) demonstrated sicca recurrence.

Conclusions

In this largest cohort to date of ICI-associated sicca syndrome, we confirm frequent improvement with steroids and/or supportive care and suggest a greater than previously appreciated risk of recurrence with rechallenge.

Schlagwörter

Stichwörter der Autor:innen

Sjogren’s diseaseimmune checkpoint inhibitorsimmune-related adverse eventsimmunotherapysicca syndromexerostomia

Autor:innen und Institutionen

  • Division of Rheumatology and Immunology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

ORCID-Profile: Meridith L Balbach

Förderung

  • NIH HHS
  • Department of Defense
  • NIH
  • DOD
  • Susan and Luke Simons Directorship

Zitieren

APA

Balbach, M. L., & Johnson, D. B. (2026). Clinical Characteristics and Management of Immune Checkpoint Inhibitor-Associated Sicca Syndrome. Cancers, 18(11), 1836. https://doi.org/10.3390/cancers18111836

Vancouver

Balbach ML, Johnson DB. Clinical Characteristics and Management of Immune Checkpoint Inhibitor-Associated Sicca Syndrome. Cancers. 2026;18(11):1836. doi:10.3390/cancers18111836

BibTeX
@article{Balbach2026,
  author = {Balbach, Meridith L and Johnson, Douglas B},
  title = {Clinical Characteristics and Management of Immune Checkpoint Inhibitor-Associated Sicca Syndrome},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {11},
  pages = {1836},
  doi = {10.3390/cancers18111836}
}
Kostenlos starten →